Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cue Biopharma reports robust clinical data and strategic partnerships

Cue Biopharma's Q4 2022 Earnings Call highlighted strong clinical data, strategic partnerships, and upcoming milestones that position the company for growth and innovation in the biopharmaceutical sector.
While facing challenges in determining optimal registration paths and patient stratification, Cue Biopharma remains focused on leveraging opportunities through partnerships, therapeutic breakthroughs, and financial stability.
With a clear focus on advancing their pipeline, Cue Biopharma aims to drive therapeutic advancements, expand their portfolio, and establish themselves as a key player in oncology treatments.

Cue Biopharma reports strong Q2 performance and eyes transformative 2024

Cue Biopharma's Q2 2023 performance showcased revenue growth, strong cash position, and promising clinical data from trials, underlining the company's commitment to precision immunotherapy in cancer treatment.
The company's strengths in harnessing natural immune signals, achieving significant antitumor activity, and exploring rational combinations position Cue Biopharma for transformative advancements.
Challenges in decision-making, dose determination, and regulatory pathways must be navigated, but opportunities in FDA resolutions, strategic decisions, and milestone achievements abound.
With a focus on data interpretation, partnerships, and transformative therapies, Cue Biopharma is poised for an exciting and impactful 2024 with multiple milestones and growth prospects.

Cue Biopharma reports positive trial outcomes and explores strategic partnerships

Cue Biopharma's Q3 showcased strong clinical progress and financial stability.
The company's Immuno-STAT platform trials displayed promising results.
Challenges include regulatory pathways and trial expansion plans.
Opportunities lie in strategic partnerships and exploring new treatment combinations.

Cue Biopharma reports solid financials and advances in immunotherapy

Cue Biopharma's financials show steady revenue growth and prudent expense management, ensuring operational funding into 2025.
The company's strengths lie in its focused approach to developing immunotherapeutic biologics and positive trial updates in oncology and autoimmune diseases.
Challenges include strategic decision-making on partnerships, trial design, and managing trial outcome expectations based on industry data.
Opportunities exist in strategic partnerships, advancements in oncology programs, and upcoming data presentations offering insights for stakeholders.

Cue Biopharma advances autoimmune programs and partnerships for treatment innovation

Cue Biopharma's focus on autoimmune programs and strategic partnerships reflects a commitment to redefining treatment standards for cancer and autoimmune diseases. Progress with key programs and the Immuno-STAT platform demonstrates potential for targeted therapies with improved efficacy and safety. Overcoming challenges in market conditions and regulatory landscapes while seizing opportunities in program advancements and partnerships will be critical for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, announced today three poster presentations highlighting the Company's clinical and pipeline progress at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020). The posters include a clinical update on CUE-101, the lead drug candidate from the IL-2 based CUE-100 series, and data supporting the potential of the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform to selectively engage and modulate targeted T cells within the body in a manner that can address a broad range of indications.

Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today three poster presentations at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020).

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development

Cue Biopharma Welcomes Tamar Howson to its Board of Directors

Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity

Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds

Cue Biopharma (CUE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Cue Biopharma (CUE) Catches Eye: Stock Jumps 5.2%

CAMBRIDGE, Mass., Sept.  03, 2020  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Baird Global Healthcare Conference on Wednesday, September 9, 2020, the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020 and the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 23, 2020. The Company will also participate in Citi's 15th Annual BioPharma Virtual Conference on September 9-10, 2020.

Cue Biopharma to Present at Upcoming Investor Conferences in September 2020

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Aug.  31, 2020  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the second quarter of 2020.

Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates

CAMBRIDGE, Mass., Aug.  24, 2020  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring Neo-STAT™, the Company’s next generation Immuno-STAT™ (Selective Targeting and Alteration of T cells) scaffold, at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit. Neo-STAT biologics are designed for targeted modulation of tumor-specific T cells with enhanced antigen modularity.

Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Cue Biopharma, Inc. (CUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

CAMBRIDGE, Mass., July  28, 2020  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the body, announced today it has advanced CUE-101 into cohort 5 in its ongoing multicenter, open-label, dose escalation Phase 1 monotherapy trial in patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ HNSCC) ( NCT03978689 ).

Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine

Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily

CAMBRIDGE, Mass., June  15, 2020  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the body, is providing an update on its Phase 1 trial of CUE-101 monotherapy as second-line or later therapy for patients with HPV+ recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).  

Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q1 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., May  19, 2020  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the first quarter 2020.

Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights

CAMBRIDGE, Mass., May  18, 2020  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring pre-clinical data on CUE-102/A02 and CUE-102/A24, the company’s second and third drug candidates from the CUE-100 series at the  American Association for Cancer Research (AACR) Virtual Annual Meeting II . CUE-102 biologics are Immuno-STATs™ (Selective Targeting and Alteration of T cells) designed to selectively target and expand Wilms’ tumor 1 (WT1) specific T cells for the treatment of patients with solid and hematological cancers.

Cue Biopharma to Present at AACR Virtual Annual Meeting

Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series

Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University

Everbridge

Fiverr

Dynamic New Players Gain Momentum In Digital, Data And Patient-Centric Space

Avenue Therapeutics

Gaia

PJT Partners

SpartanNash

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.

5 Top Small-Cap Stocks Braving Coronavirus Bloodbath

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q4 2019 Results - Earnings Call Transcript

Cue Biopharma (CUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Cue Biopharma (CUE) Ahead of Earnings

Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: Should You Buy?

Cue Biopharma: An Innovative But Risky Immunology Pick For 2020

HarborOne Bancorp

Horizon Technology Finance

Independent Bank

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

4 Stocks in Focus as New Analysts Show Interest

CRISPR Therapeutics

Vertex Pharmaceuticals

Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.

News for Cue Biopharma Stock (CUE)